Compare · COGT vs JNJ
COGT vs JNJ
Side-by-side comparison of Cogent Biosciences Inc. (COGT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COGT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $634.06B, about 93.3x COGT ($6.79B).
- Over the past year, COGT is up 228.1% and JNJ is up 58.5% - COGT leads by 169.6 points.
- JNJ has been more active in the news (12 items in the past 4 weeks vs 1 for COGT).
- JNJ has more recent analyst coverage (25 ratings vs 17 for COGT).
- Company
- Cogent Biosciences Inc.
- Johnson & Johnson
- Price
- $39.66-1.45%
- $263.42+1.56%
- Market cap
- $6.79B
- $634.06B
- 1M return
- +5.63%
- +9.30%
- 1Y return
- +228.08%
- +58.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 12
- Recent ratings
- 17
- 25
Cogent Biosciences Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest COGT
- SEC Form 4 filed by Director Ferrante Karen Jean
- Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
- Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
- Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
- Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
- President and CEO Robbins Andrew R received a gift of 160,000 shares and gifted 160,000 shares, decreasing direct ownership by 24% to 497,503 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.
- Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
- EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026